Phathom Pharmaceuticals, Inc. PHAT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $58.3M+104% | $57.58M+94.1% | $49.5M+203% | $39.5M+439% | $28.52M+1,392% | ||
| $12M+222% | $7.65M+100% | $6.19M+163% | $5.04M+266% | $3.72M+774% | ||
| $46.31M+86.8% | $49.94M+93.2% | $43.31M+209% | $34.47M+479% | $24.8M+1,569% | ||
| 79.4%-7.5pp | 86.7%-0.4pp | 87.5%+1.9pp | 87.2%+6.0pp | 86.9%+9.2pp | ||
| $7.77M-15.4% | $7.49M-12.7% | $7.03M-19.2% | $9.08M+23.0% | $9.18M-2.6% | ||
| $54.01M-42.8% | $48.37M-36.9% | $51.56M-32.2% | $85.31M+12.4% | $94.47M+52.4% | ||
| $61.78M-40.4% | $55.86M-34.5% | $58.59M-30.9% | $94.39M+13.4% | $103.66M+45.1% | ||
| $61.78M-40.4% | $55.86M-34.5% | $58.59M-30.9% | $94.39M+13.4% | $103.66M+45.1% | ||
| -$15.48M+80.4% | -$5.93M+90.0% | -$15.27M+78.4% | -$59.92M+22.5% | -$78.86M-12.7% | ||
| -26.5%+250pp | -10.3%+190pp | -30.8%+402pp | -151.7%+904pp | -276.5%+3,382pp | ||
| $15.8M-12.6% | $16.42M-11.7% | $16.11M-12.9% | $17.52M-1.4% | $18.07M+5.3% | ||
| $1.74M-34.2% | $1.2M-65.7% | $1.41M-61.9% | $1.79M-50.7% | $2.64M-38.8% | ||
| -$14.89M+3.6% | -$15.22M-1.2% | -$14.7M+0.5% | -$15.89M-12.3% | -$15.45M-19.8% | ||
| -$30.37M+67.8% | -$21.15M+71.6% | -$29.97M+65.0% | -$75.81M+17.1% | -$94.32M-13.8% | ||
| -52.1%+279pp | -36.7%+214pp | -60.5%+463pp | -191.9%+1,057pp | -330.7%+4,003pp | ||
| -$0.37+71.8% | -$0.27+73.0% | -$0.41+68.9% | -$1.05+32.7% | -$1.31+7.7% | ||
| -$0.37+71.8% | -$0.27+73.0% | -$0.41+68.9% | -$1.05+32.7% | -$1.31+7.7% | ||
| 82.1M+14.0% | 72.9M+15.4% | 73.4M+13.6% | 72.5M+23.8% | 72M+23.3% | ||
| 82.1M+14.0% | 72.9M+15.4% | 73.4M+13.6% | 72.5M+23.8% | 72M+23.3% | ||
| -$831K-3,677% | -$5K— | -$7K+12.5% | -$155K-2,483% | -$22K+48.8% | ||
| -$15.48M+80.4% | -$5.93M+90.0% | -$15.27M+78.4% | -$59.92M+22.5% | -$78.86M-12.7% | ||
| -$15.37M+80.5% | -$5.8M+90.2% | -$15.12M+78.6% | -$59.75M+22.5% | -$78.69M-12.8% | ||
| -$15.37M+80.5% | -$5.8M+90.2% | -$15.12M+78.6% | -$59.75M+22.5% | -$78.69M-12.8% | ||
| -26.4%+250pp | -10.1%+190pp | -30.5%+401pp | -151.3%+901pp | -275.9%+3,372pp | ||
| -$15.48M+80.4% | -$5.93M+90.0% | -$15.27M+78.4% | -$59.92M+22.5% | -$78.86M-12.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) generated $204.9M in revenue over the trailing twelve months, up 150.3% year over year.
- Is Phathom Pharmaceuticals, Inc. profitable?
- Phathom Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months, a -76.8% net margin.
- What are Phathom Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 84.9% and operating margin is -47.1%, with a -76.8% net margin.
- What is Phathom Pharmaceuticals, Inc.'s earnings per share?
- Phathom Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.10.
- Where does Phathom Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
